Where can I read MRK's latest 10-K?

MRK's latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.

When did MRK last file an 8-K?

On Aug 4, 2026: results of operations. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 4, 2026.

Are MRK insiders buying or selling?

Over the last 13 months insiders sold $70.7M in 21 sales and bought nothing on the open market; 120 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Guindo Chirfi (EVP, Access, Policy & Comms) sold 10,000 shares on Aug 13, 2026 for $1.4M. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.

How many SEC filings has MRK made?

3,028 filings are on EDGAR under the registrant records that have been Merck & Co. Inc., going back to 1994; 2,020 of them are insider ownership forms (Forms 3, 4, 5 and 144).

Share this page

MRK

$144.30+0.34%

as of close, Oct 2, 2026

☾ AH $144.30 +0.34%

Merck & Co. Inc.Stock · HealthcareDow Jones 1.5%S&P 500 0.5%Russell 1000 0.5%US Stock Market 0.4%Russell 3000 0.4%MSCI World 0.3%MSCI ACWI 0.3%S&P 500 Equal Weight 0.2%

PeersMRNALLYUNHJNJTMOAMGN

MRK SEC filings (2026)

CIK 310158 · Pharmaceutical Preparations (SIC 2834) · incorporated in NJ · fiscal year ends in December

3,028 filings on EDGAR since 1994 · 42 annual, 99 quarterly, 280 current · financial statements · earnings

Latest 10-K

Feb 24, 2026

fiscal year to Dec 31, 2025

Latest 10-Q

Aug 7, 2026

quarter to Jun 30, 2026

Latest 8-K

Aug 4, 2026

Results of operations

Last earnings release

Aug 4, 2026

−$0.13 vs −$0.26 · ▲ 0.2%

Filings on file

3,028

since 1994, 2,020 insider forms

What happened, last 12 months#

Every earnings release with its print, every report with its quarter, the other 8-Ks by what they covered, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.

December 2025

Dec 48-K8-K · Other events

November 2025

Nov 5ReportQuarterly report, Q3 2025 — revenue $17.28B (+4% y/y), net income $5.79B, EPS $2.32

October 2025

Oct 30EarningsEarnings release — EPS $2.58 vs $2.36 est. (+9.3%); revenue $17.28B (+4% y/y) 0.3%

Insider transactions#

What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.

Over the last 13 months insiders sold $70.7M in 21 sales and bought nothing on the open market; 120 other transactions (awards, exercises, tax withholding, gifts and plan purchases).

Date	Insider	Action	Shares	Price	Value	Held after	Filing
Aug 13, 2026Form 4	Guindo ChirfiEVP, Access, Policy & CommsSold · $1.4M · 10,000 sh	Sold	10,000	$135.00	$1.4M	36,613.127	Form 4
Aug 12, 2026Form 4	Zachary JenniferEVP, General CounselSold · $10.7M · 80,315 sh	Sold	80,315	$133.46	$10.7M	45,509.254	Form 4
Aug 12, 2026Form 4	DeLuca Richard R.EVP&Pres, Merck Animal HeallthSold · $1.5M · 11,699 sh	Sold	11,699	$131.61–$132.04	$1.5M	110,167.07	Form 4
Aug 11, 2026Form 4	DeLuca Richard R.EVP&Pres, Merck Animal HeallthSold · $1.7M · 12,837 sh	Sold	12,837	$131.33–$132.35	$1.7M	121,866.07	Form 4
Aug 10, 2026Form 4	DeLuca Richard R.EVP&Pres, Merck Animal HeallthSold · $2.7M · 20,784 sh	Sold	20,784	$130.43	$2.7M	134,703.07	Form 4
Aug 6, 2026Form 4	Guindo ChirfiEVP, Access, Policy & CommsSold · $2.0M · 15,000 sh	Sold	15,000	$131.00	$2.0M	46,613.127	Form 4
Aug 6, 2026Form 4	DeLuca Richard R.EVP&Pres, Merck Animal HeallthSold · $789K · 6,050 sh	Sold	6,050	$130.23–$131.02	$789K	155,487.07	Form 4
Aug 5, 2026Form 4	Williams David MichaelEVP,Chief Info&Digital OfficerSold · $6.8M · 52,847 sh	Sold	52,847	$128.77	$6.8M	31,716.037	Form 4
Aug 5, 2026Form 4	Maraldo David R.EVP & Pres. MMDSold · $2.4M · 18,706 sh	Sold	18,706	$128.72	$2.4M	18,212.434	Form 4
Feb 12, 2026Form 4	Guindo ChirfiChief Marketing OfficerSold · $1.2M · 10,000 sh	Sold	10,000	$121.46	$1.2M	60,615.127	Form 4
Feb 10, 2026Form 4	Li Dean YExecutive VP & President, MRLSold · $1.2M · 10,235 sh	Sold	10,235	$117.52	$1.2M	92,035.05	Form 4
Feb 9, 2026Form 4	Zachary JenniferEVP, General CounselSold · $14.5M · 121,573 sh	Sold	121,573	$119.15	$14.5M	68,915.671	Form 4
Feb 9, 2026Form 4	Guindo ChirfiChief Marketing OfficerSold · $1.2M · 10,000 sh	Sold	10,000	$118.41	$1.2M	70,615.127	Form 4
Feb 6, 2026Form 4	DeLuca Richard R.EVP&Pres, Merck Animal HeallthSold · $4.6M · 37,685 sh	Sold	37,685	$120.92	$4.6M	160,173.834	Form 4
Feb 6, 2026Form 4	Oosthuizen Johannes JacobusPresident, U.S. MarketSold · $1.8M · 15,000 sh	Sold	15,000	$121.87	$1.8M	21,197.389	Form 4
Feb 6, 2026Form 4	Williams David MichaelEVP,Chief Info&Digital OfficerSold · $610K · 5,000 sh	Sold	5,000	$121.91	$610K	30,837.743	Form 4
Feb 5, 2026Form 4	Guindo ChirfiChief Marketing OfficerSold · $2.4M · 20,000 sh	Sold	20,000	$121.88	$2.4M	80,615.127	Form 4
Feb 4, 2026Form 4	Davis Robert MChairman, CEO & President · DirectorSold · $5.6M · 47,434 sh	Sold	47,434	$117.38–$118.35	$5.6M	443,601.757	Form 4
Feb 4, 2026Form 4	Litchfield CarolineEVP & CFOSold · $5.0M · 41,997 sh	Sold	41,997	$119.61	$5.0M	90,192.194	Form 4
Feb 4, 2026Form 4	Li Dean YExecutive VP & President, MRLSold · $1.8M · 15,087 sh	Sold	15,087	$118.77	$1.8M	102,270.05	Form 4
Feb 4, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerSold · $766K · 6,400 sh	Sold	6,400	$119.68	$766K	8,204.816	Form 4

Awards, exercises, withholding and plan purchases · 120 transactions

Date	Insider	Action	Shares	Price	Value	Held after	Filing
Sep 30, 2026Form 4	Coe Mary EllenDirectorAward · $30K · 206.455 sh	Award	206.455	$145.31	$30K	32,419.866	Form 4
Sep 30, 2026Form 4	Karsanbhai Surendralal LancaDirectorAward · $16K · 111.83 sh	Award	111.83	$145.31	$16K	5,667.012	Form 4
Sep 30, 2026Form 4	Seidman Christine EDirectorAward · $8,125 · 55.915 sh	Award	55.915	$145.31	$8,125	21,490.401	Form 4
Aug 12, 2026Form 4	Zachary JenniferEVP, General CounselExercise or conversion · $6.0M · 54,927 sh	Exercise or conversion	54,927	$84.71–$117.89	$6.0M	125,824.254	Form 4
Aug 12, 2026Form 4	Zachary JenniferEVP, General CounselExercise or conversion · Stock Option (Right to Buy) · $0 · 54,927 sh	Exercise or conversion· Stock Option (Right to Buy)	54,927	$0.00	$0	0	Form 4
Aug 5, 2026Form 4	Williams David MichaelEVP,Chief Info&Digital OfficerExercise or conversion · $3.9M · 52,847 sh	Exercise or conversion	52,847	$73.73–$77.62	$3.9M	66,421.037	Form 4
Aug 5, 2026Form 4	Maraldo David R.EVP & Pres. MMDExercise or conversion · $1.5M · 18,706 sh	Exercise or conversion	18,706	$73.73–$87.10	$1.5M	20,898.434	Form 4
Aug 5, 2026Form 4	Williams David MichaelEVP,Chief Info&Digital OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 52,847 sh	Exercise or conversion· Stock Option (Right to Buy)	52,847	$0.00	$0	0	Form 4
Aug 5, 2026Form 4	Maraldo David R.EVP & Pres. MMDExercise or conversion · Stock Option (Right to Buy) · $0 · 18,706 sh	Exercise or conversion· Stock Option (Right to Buy)	18,706	$0.00	$0	5,374	Form 4
Jun 30, 2026Form 4	Coe Mary EllenDirectorAward · $30K · 233.463 sh	Award	233.463	$128.50	$30K	31,999.102	Form 4
Jun 30, 2026Form 4	Karsanbhai Surendralal LancaDirectorAward · $16K · 126.459 sh	Award	126.459	$128.50	$16K	5,518.802	Form 4
Jun 30, 2026Form 4	Seidman Christine EDirectorAward · $8,125 · 63.23 sh	Award	63.23	$128.50	$8,125	21,291.269	Form 4
May 29, 2026Form 4	BAKER DOUGLAS M JRDirectorAward · $220K · 1,853.1 sh	Award	1,853.1	$118.72	$220K	11,518.208	Form 4
May 29, 2026Form 4	Craig Pamela J.DirectorAward · $220K · 1,853.1 sh	Award	1,853.1	$118.72	$220K	34,944.93	Form 4
May 29, 2026Form 4	GLOCER THOMAS HDirectorAward · $220K · 1,853.1 sh	Award	1,853.1	$118.72	$220K	110,911.759	Form 4
May 29, 2026Form 4	LAVIZZO-MOUREY RISA JDirectorAward · $220K · 1,853.1 sh	Award	1,853.1	$118.72	$220K	17,749.352	Form 4
May 29, 2026Form 4	Mayo StephenDirectorAward · $220K · 1,853.1 sh	Award	1,853.1	$118.72	$220K	14,824.52	Form 4
May 29, 2026Form 4	Rothman PaulDirectorAward · $220K · 1,853.1 sh	Award	1,853.1	$118.72	$220K	34,944.942	Form 4
May 29, 2026Form 4	RUSSO PATRICIA FDirectorAward · $220K · 1,853.1 sh	Award	1,853.1	$118.72	$220K	62,390.752	Form 4
May 29, 2026Form 4	Seidman Christine EDirectorAward · $220K · 1,853.1 sh	Award	1,853.1	$118.72	$220K	21,228.039	Form 4
May 29, 2026Form 4	THULIN INGE GDirectorAward · $220K · 1,853.1 sh	Award	1,853.1	$118.72	$220K	27,469.711	Form 4
May 29, 2026Form 4	Coe Mary EllenDirectorAward · $220K · 1,853.1 sh	Award	1,853.1	$118.72	$220K	31,765.639	Form 4
May 29, 2026Form 4	Karsanbhai Surendralal LancaDirectorAward · $220K · 1,853.1 sh	Award	1,853.1	$118.72	$220K	5,392.343	Form 4
May 29, 2026Form 4	Warden Kathy JDirectorAward · $220K · 1,853.1 sh	Award	1,853.1	$118.72	$220K	17,890.292	Form 4
May 5, 2026Form 4	Davis Robert MChairman, CEO & President · DirectorAward · Stock Option (Right to Buy) · $0 · 139,697 sh	Award· Stock Option (Right to Buy)	139,697	$0.00	$0	139,697	Form 4
May 5, 2026Form 4	Li Dean YExecutive VP & President, MRLAward · Stock Option (Right to Buy) · $0 · 58,207 sh	Award· Stock Option (Right to Buy)	58,207	$0.00	$0	58,207	Form 4
May 5, 2026Form 4	Davis Robert MChairman, CEO & President · DirectorAward · Restricted Stock Unit · $0 · 47,724 sh	Award· Restricted Stock Unit	47,724	$0.00	$0	47,724	Form 4
May 5, 2026Form 4	Litchfield CarolineEVP & CFOAward · Stock Option (Right to Buy) · $0 · 46,566 sh	Award· Stock Option (Right to Buy)	46,566	$0.00	$0	46,566	Form 4
May 5, 2026Form 4	Foard BrianEVP, Specialty, Pharma, & IDAward · Restricted Stock Unit · $0 · 45,956 sh	Award· Restricted Stock Unit	45,956	$0.00	$0	35,351	Form 4
May 5, 2026Form 4	Zachary JenniferEVP, General CounselAward · Stock Option (Right to Buy) · $0 · 35,312 sh	Award· Stock Option (Right to Buy)	35,312	$0.00	$0	35,312	Form 4
May 5, 2026Form 4	DeLuca Richard R.EVP&Pres, Merck Animal HeallthAward · Stock Option (Right to Buy) · $0 · 34,924 sh	Award· Stock Option (Right to Buy)	34,924	$0.00	$0	34,924	Form 4
May 5, 2026Form 4	Oosthuizen Johannes JacobusEVP, Oncology & Int?lAward · Stock Option (Right to Buy) · $0 · 31,044 sh	Award· Stock Option (Right to Buy)	31,044	$0.00	$0	31,044	Form 4
May 5, 2026Form 4	Foard BrianEVP, Specialty, Pharma, & IDAward · Stock Option (Right to Buy) · $0 · 31,044 sh	Award· Stock Option (Right to Buy)	31,044	$0.00	$0	31,044	Form 4
May 5, 2026Form 4	Larson Betty DEVP, Chief HR OfficerAward · Stock Option (Right to Buy) · $0 · 23,283 sh	Award· Stock Option (Right to Buy)	23,283	$0.00	$0	23,283	Form 4
May 5, 2026Form 4	Maraldo David R.EVP & Pres. MMDAward · Stock Option (Right to Buy) · $0 · 21,731 sh	Award· Stock Option (Right to Buy)	21,731	$0.00	$0	21,731	Form 4
May 5, 2026Form 4	Li Dean YExecutive VP & President, MRLAward · Restricted Stock Unit · $0 · 19,885 sh	Award· Restricted Stock Unit	19,885	$0.00	$0	19,885	Form 4
May 5, 2026Form 4	Guindo ChirfiEVP, Access, Policy & CommsAward · Stock Option (Right to Buy) · $0 · 19,402 sh	Award· Stock Option (Right to Buy)	19,402	$0.00	$0	19,402	Form 4
May 5, 2026Form 4	Litchfield CarolineEVP & CFOAward · Restricted Stock Unit · $0 · 15,908 sh	Award· Restricted Stock Unit	15,908	$0.00	$0	15,908	Form 4
May 5, 2026Form 4	Williams David MichaelEVP,Chief Info&Digital OfficerAward · Stock Option (Right to Buy) · $0 · 13,582 sh	Award· Stock Option (Right to Buy)	13,582	$0.00	$0	13,582	Form 4
May 5, 2026Form 4	Zachary JenniferEVP, General CounselAward · Restricted Stock Unit · $0 · 12,064 sh	Award· Restricted Stock Unit	12,064	$0.00	$0	12,064	Form 4
May 5, 2026Form 4	DeLuca Richard R.EVP&Pres, Merck Animal HeallthAward · Restricted Stock Unit · $0 · 11,931 sh	Award· Restricted Stock Unit	11,931	$0.00	$0	11,931	Form 4
May 5, 2026Form 4	Oosthuizen Johannes JacobusEVP, Oncology & Int?lAward · Restricted Stock Unit · $0 · 10,605 sh	Award· Restricted Stock Unit	10,605	$0.00	$0	10,605	Form 4
May 5, 2026Form 4	Larson Betty DEVP, Chief HR OfficerAward · Restricted Stock Unit · $0 · 7,954 sh	Award· Restricted Stock Unit	7,954	$0.00	$0	7,954	Form 4
May 5, 2026Form 4	Maraldo David R.EVP & Pres. MMDAward · Restricted Stock Unit · $0 · 7,424 sh	Award· Restricted Stock Unit	7,424	$0.00	$0	7,424	Form 4
May 5, 2026Form 4	Guindo ChirfiEVP, Access, Policy & CommsAward · Restricted Stock Unit · $0 · 6,628 sh	Award· Restricted Stock Unit	6,628	$0.00	$0	6,628	Form 4
May 5, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerAward · Stock Option (Right to Buy) · $0 · 5,045 sh	Award· Stock Option (Right to Buy)	5,045	$0.00	$0	5,045	Form 4
May 5, 2026Form 4	Williams David MichaelEVP,Chief Info&Digital OfficerAward · Restricted Stock Unit · $0 · 4,640 sh	Award· Restricted Stock Unit	4,640	$0.00	$0	4,640	Form 4
May 5, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerAward · Restricted Stock Unit · $0 · 2,298 sh	Award· Restricted Stock Unit	2,298	$0.00	$0	2,298	Form 4
May 2, 2026Form 4	Maraldo David R.EVP & Pres. MMDExercise or conversion · $62K · 552 sh	Exercise or conversion	552	$112.16	$62K	18,371.434	Form 4
May 2, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerExercise or conversion · $43K · 383 sh	Exercise or conversion	383	$112.16	$43K	9,520.315	Form 4
May 2, 2026Form 4	Maraldo David R.EVP & Pres. MMDTax withholding · $18K · 159 sh	Tax withholding	159	$112.16	$18K	18,212.434	Form 4
May 2, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerTax withholding · $15K · 132 sh	Tax withholding	132	$112.16	$15K	9,388.315	Form 4
May 2, 2026Form 4	Maraldo David R.EVP & Pres. MMDExercise or conversion · Restricted Stock Unit · $0 · 552 sh	Exercise or conversion· Restricted Stock Unit	552	$0.00	$0	0	Form 4
May 2, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerExercise or conversion · Restricted Stock Unit · $0 · 383 sh	Exercise or conversion· Restricted Stock Unit	383	$0.00	$0	0	Form 4
Apr 30, 2026Form 4	Larson Betty DEVP, Chief HR OfficerExercise or conversion · $1.3M · 11,350 sh	Exercise or conversion	11,350	$110.95	$1.3M	18,917	Form 4
Apr 30, 2026Form 4	Larson Betty DEVP, Chief HR OfficerTax withholding · $571K · 5,143 sh	Tax withholding	5,143	$110.95	$571K	13,774	Form 4
Apr 30, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerExercise or conversion · $51K · 464 sh	Exercise or conversion	464	$110.95	$51K	9,296.315	Form 4
Apr 30, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerTax withholding · $18K · 159 sh	Tax withholding	159	$110.95	$18K	9,137.315	Form 4
Apr 30, 2026Form 4	Larson Betty DEVP, Chief HR OfficerExercise or conversion · Restricted Stock Unit · $0 · 11,350 sh	Exercise or conversion· Restricted Stock Unit	11,350	$0.00	$0	11,350	Form 4
Apr 30, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerExercise or conversion · Restricted Stock Unit · $0 · 464 sh	Exercise or conversion· Restricted Stock Unit	464	$0.00	$0	465	Form 4
Apr 29, 2026Form 4	Davis Robert MChairman, CEO & President · DirectorExercise or conversion · $1.5M · 13,300 sh	Exercise or conversion	13,300	$110.03	$1.5M	456,901.757	Form 4
Apr 29, 2026Form 4	Davis Robert MChairman, CEO & President · DirectorTax withholding · $721K · 6,551 sh	Tax withholding	6,551	$110.03	$721K	450,350.757	Form 4
Apr 29, 2026Form 4	Li Dean YExecutive VP & President, MRLExercise or conversion · $520K · 4,722 sh	Exercise or conversion	4,722	$110.03	$520K	96,757.05	Form 4
Apr 29, 2026Form 4	Litchfield CarolineEVP & CFOExercise or conversion · $433K · 3,935 sh	Exercise or conversion	3,935	$110.03	$433K	94,238.657	Form 4
Apr 29, 2026Form 4	Zachary JenniferEVP, General CounselExercise or conversion · $325K · 2,951 sh	Exercise or conversion	2,951	$110.03	$325K	72,351.254	Form 4
Apr 29, 2026Form 4	Chattopadhyay SanatExe V-P & Pres. MMDExercise or conversion · $286K · 2,597 sh	Exercise or conversion	2,597	$110.03	$286K	16,477	Form 4
Apr 29, 2026Form 4	DeLuca Richard R.EVP&Pres, Merck Animal HeallthExercise or conversion · $277K · 2,518 sh	Exercise or conversion	2,518	$110.03	$277K	162,778.07	Form 4
Apr 29, 2026Form 4	Li Dean YExecutive VP & President, MRLTax withholding · $256K · 2,326 sh	Tax withholding	2,326	$110.03	$256K	94,431.05	Form 4
Apr 29, 2026Form 4	Larson Betty DEVP, Chief HR OfficerExercise or conversion · $229K · 2,085 sh	Exercise or conversion	2,085	$110.03	$229K	8,282	Form 4
Apr 29, 2026Form 4	Guindo ChirfiEVP, Access, Policy & CommsExercise or conversion · $216K · 1,967 sh	Exercise or conversion	1,967	$110.03	$216K	62,582.127	Form 4
Apr 29, 2026Form 4	Litchfield CarolineEVP & CFOTax withholding · $213K · 1,938 sh	Tax withholding	1,938	$110.03	$213K	92,300.657	Form 4
Apr 29, 2026Form 4	Zachary JenniferEVP, General CounselTax withholding · $160K · 1,454 sh	Tax withholding	1,454	$110.03	$160K	70,897.254	Form 4
Apr 29, 2026Form 4	Oosthuizen Johannes JacobusEVP, Oncology & Int?lExercise or conversion · $152K · 1,377 sh	Exercise or conversion	1,377	$110.03	$152K	22,574.389	Form 4
Apr 29, 2026Form 4	Williams David MichaelEVP,Chief Info&Digital OfficerExercise or conversion · $152K · 1,377 sh	Exercise or conversion	1,377	$110.03	$152K	32,395.037	Form 4
Apr 29, 2026Form 4	DeLuca Richard R.EVP&Pres, Merck Animal HeallthTax withholding · $137K · 1,241 sh	Tax withholding	1,241	$110.03	$137K	161,537.07	Form 4
Apr 29, 2026Form 4	Chattopadhyay SanatExe V-P & Pres. MMDTax withholding · $124K · 1,130 sh	Tax withholding	1,130	$110.03	$124K	15,347	Form 4
Apr 29, 2026Form 4	Guindo ChirfiEVP, Access, Policy & CommsTax withholding · $107K · 969 sh	Tax withholding	969	$110.03	$107K	61,613.127	Form 4
Apr 29, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerExercise or conversion · $104K · 944 sh	Exercise or conversion	944	$110.03	$104K	9,156.315	Form 4
Apr 29, 2026Form 4	Larson Betty DEVP, Chief HR OfficerTax withholding · $79K · 715 sh	Tax withholding	715	$110.03	$79K	7,567	Form 4
Apr 29, 2026Form 4	Oosthuizen Johannes JacobusEVP, Oncology & Int?lTax withholding · $75K · 679 sh	Tax withholding	679	$110.03	$75K	21,895.389	Form 4
Apr 29, 2026Form 4	Williams David MichaelEVP,Chief Info&Digital OfficerTax withholding · $75K · 679 sh	Tax withholding	679	$110.03	$75K	31,716.037	Form 4
Apr 29, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerTax withholding · $36K · 324 sh	Tax withholding	324	$110.03	$36K	8,832.315	Form 4
Apr 29, 2026Form 4	Davis Robert MChairman, CEO & President · DirectorExercise or conversion · Restricted Stock Unit · $0 · 13,300 sh	Exercise or conversion· Restricted Stock Unit	13,300	$0.00	$0	26,601	Form 4
Apr 29, 2026Form 4	Li Dean YExecutive VP & President, MRLExercise or conversion · Restricted Stock Unit · $0 · 4,722 sh	Exercise or conversion· Restricted Stock Unit	4,722	$0.00	$0	9,444	Form 4
Apr 29, 2026Form 4	Litchfield CarolineEVP & CFOExercise or conversion · Restricted Stock Unit · $0 · 3,935 sh	Exercise or conversion· Restricted Stock Unit	3,935	$0.00	$0	7,870	Form 4
Apr 29, 2026Form 4	Zachary JenniferEVP, General CounselExercise or conversion · Restricted Stock Unit · $0 · 2,951 sh	Exercise or conversion· Restricted Stock Unit	2,951	$0.00	$0	5,903	Form 4
Apr 29, 2026Form 4	Chattopadhyay SanatExe V-P & Pres. MMDExercise or conversion · Restricted Stock Unit · $0 · 2,597 sh	Exercise or conversion· Restricted Stock Unit	2,597	$0.00	$0	5,194	Form 4
Apr 29, 2026Form 4	DeLuca Richard R.EVP&Pres, Merck Animal HeallthExercise or conversion · Restricted Stock Unit · $0 · 2,518 sh	Exercise or conversion· Restricted Stock Unit	2,518	$0.00	$0	5,037	Form 4
Apr 29, 2026Form 4	Larson Betty DEVP, Chief HR OfficerExercise or conversion · Restricted Stock Unit · $0 · 2,085 sh	Exercise or conversion· Restricted Stock Unit	2,085	$0.00	$0	4,172	Form 4
Apr 29, 2026Form 4	Guindo ChirfiEVP, Access, Policy & CommsExercise or conversion · Restricted Stock Unit · $0 · 1,967 sh	Exercise or conversion· Restricted Stock Unit	1,967	$0.00	$0	3,935	Form 4
Apr 29, 2026Form 4	Oosthuizen Johannes JacobusEVP, Oncology & Int?lExercise or conversion · Restricted Stock Unit · $0 · 1,377 sh	Exercise or conversion· Restricted Stock Unit	1,377	$0.00	$0	2,755	Form 4
Apr 29, 2026Form 4	Williams David MichaelEVP,Chief Info&Digital OfficerExercise or conversion · Restricted Stock Unit · $0 · 1,377 sh	Exercise or conversion· Restricted Stock Unit	1,377	$0.00	$0	2,755	Form 4
Apr 29, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerExercise or conversion · Restricted Stock Unit · $0 · 944 sh	Exercise or conversion· Restricted Stock Unit	944	$0.00	$0	1,889	Form 4
Mar 31, 2026Form 4	GLOCER THOMAS HDirectorAward · $49K · 405.271 sh	Award	405.271	$120.29	$49K	108,293.493	Form 4
Mar 31, 2026Form 4	Coe Mary EllenDirectorAward · $30K · 249.397 sh	Award	249.397	$120.29	$30K	29,702.652	Form 4
Mar 31, 2026Form 4	Seidman Christine EDirectorAward · $8,125 · 67.545 sh	Award	67.545	$120.29	$8,125	19,238.328	Form 4
Feb 9, 2026Form 4	Zachary JenniferEVP, General CounselExercise or conversion · $14.5M · 121,573 sh	Exercise or conversion	121,573	$119.15	$14.5M	107,750.671	Form 4
Feb 9, 2026Form 4	Zachary JenniferEVP, General CounselExercise or conversion · Stock Option (Right to Buy) · $0 · 121,573 sh	Exercise or conversion· Stock Option (Right to Buy)	121,573	$0.00	$0	0	Form 4
Feb 6, 2026Form 4	Williams David MichaelEVP,Chief Info&Digital OfficerExercise or conversion · $388K · 5,000 sh	Exercise or conversion	5,000	$77.62	$388K	35,837.743	Form 4
Feb 6, 2026Form 4	Williams David MichaelEVP,Chief Info&Digital OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 5,000 sh	Exercise or conversion· Stock Option (Right to Buy)	5,000	$0.00	$0	4,600	Form 4
Feb 4, 2026Form 4	Litchfield CarolineEVP & CFOExercise or conversion · $2.2M · 41,997 sh	Exercise or conversion	41,997	$53.06	$2.2M	132,189.194	Form 4
Feb 4, 2026Form 4	Li Dean YExecutive VP & President, MRLExercise or conversion · $845K · 15,087 sh	Exercise or conversion	15,087	$56.04	$845K	117,357.05	Form 4
Feb 4, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerExercise or conversion · $248K · 4,000 sh	Exercise or conversion	4,000	$62.07	$248K	14,604.816	Form 4
Feb 4, 2026Form 4	Litchfield CarolineEVP & CFOExercise or conversion · Stock Option (Right to Buy) · $0 · 41,997 sh	Exercise or conversion· Stock Option (Right to Buy)	41,997	$0.00	$0	0	Form 4
Feb 4, 2026Form 4	Li Dean YExecutive VP & President, MRLExercise or conversion · Stock Option (Right to Buy) · $0 · 15,087 sh	Exercise or conversion· Stock Option (Right to Buy)	15,087	$0.00	$0	0	Form 4
Feb 4, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerExercise or conversion · Stock Option (Right to Buy) · $0 · 4,000 sh	Exercise or conversion· Stock Option (Right to Buy)	4,000	$0.00	$0	8,130	Form 4
Jan 26, 2026Form 4	Davis Robert MChairman, CEO & President · DirectorAward · $5.1M · 47,434 sh	Award	47,434	$107.40	$5.1M	491,035.757	Form 4
Jan 26, 2026Form 4	Li Dean YExecutive VP & President, MRLAward · $2.2M · 20,469 sh	Award	20,469	$107.40	$2.2M	102,270.05	Form 4
Jan 26, 2026Form 4	Litchfield CarolineEVP & CFOAward · $1.7M · 15,852 sh	Award	15,852	$107.40	$1.7M	90,192.194	Form 4
Jan 26, 2026Form 4	Chattopadhyay SanatExe V-P & Pres. MMDAward · $1.5M · 13,880 sh	Award	13,880	$107.40	$1.5M	13,880	Form 4
Jan 26, 2026Form 4	DeLuca Richard R.EVP&Pres, Merck Animal HeallthAward · $1.3M · 12,264 sh	Award	12,264	$107.40	$1.3M	197,858.834	Form 4
Jan 26, 2026Form 4	Zachary JenniferEVP, General CounselAward · $1.2M · 11,583 sh	Award	11,583	$107.40	$1.2M	68,915.671	Form 4
Jan 26, 2026Form 4	Guindo ChirfiChief Marketing OfficerAward · $1.1M · 9,865 sh	Award	9,865	$107.40	$1.1M	100,615.127	Form 4
Jan 26, 2026Form 4	Williams David MichaelEVP,Chief Info&Digital OfficerAward · $656K · 6,112 sh	Award	6,112	$107.40	$656K	30,837.743	Form 4
Jan 26, 2026Form 4	Romanelli JosephPresident, Human Health Int?lAward · $613K · 5,703 sh	Award	5,703	$107.40	$613K	28,739.343	Form 4
Jan 26, 2026Form 4	Oosthuizen Johannes JacobusPresident, U.S. MarketAward · $540K · 5,026 sh	Award	5,026	$107.40	$540K	36,197.389	Form 4
Jan 26, 2026Form 4	Smart Dalton E. IIISVP Fin. - Global ControllerAward · $114K · 1,066 sh	Award	1,066	$107.40	$114K	10,604.816	Form 4
Dec 31, 2025Form 4	GLOCER THOMAS HDirectorAward · $49K · 463.139 sh	Award	463.139	$105.26	$49K	107,075.674	Form 4
Dec 31, 2025Form 4	Coe Mary EllenDirectorAward · $30K · 285.009 sh	Award	285.009	$105.26	$30K	29,231.572	Form 4
Dec 31, 2025Form 4	Seidman Christine EDirectorAward · $8,125 · 77.19 sh	Award	77.19	$105.26	$8,125	19,025.669	Form 4

Reports and proxy statements#

Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K is described by its items. A form opens the document on EDGAR, or the filing’s index where it furnishes exhibits (an earnings release is the 8-K’s Exhibit 99.1).

2026 · 11 filings

Filed	Form	What it is	Period
Aug 7, 202610-Q	10-Q	Quarterly report, Q2 2026 — revenue $16.61B (+5% y/y), net income −$1.33B, EPS −$0.54	Jun 30, 2026
Aug 4, 20268-K	8-K	Earnings release — EPS −$0.13 vs −$0.26 est. (+50.0%); revenue $16.61B (+5% y/y) 0.2%	Aug 4, 2026
May 28, 20268-K	8-K	Shareholder vote results	May 26, 2026
May 22, 20268-K	8-K	Other events	May 22, 2026
May 4, 202610-Q	10-Q	Quarterly report, Q1 2026 — revenue $16.29B (+5% y/y), net income −$4.24B, EPS −$1.72	Mar 31, 2026
Apr 30, 20268-K	8-K	Earnings release — EPS −$1.28 vs −$1.51 est. (+15.2%); revenue $16.29B (+5% y/y) 1.6%	Apr 30, 2026
Apr 8, 2026ARS	ARS	Annual report to shareholders	Dec 31, 2025
Apr 8, 2026DEFA14A	DEFA14A	Additional proxy materials	—
Apr 8, 2026DEF 14A	DEF 14A	Proxy statement	May 26, 2026
Feb 24, 202610-K	10-K	Annual report, FY2025 — revenue $65.01B (+1% y/y), net income $18.25B, EPS $7.28	Dec 31, 2025
Feb 3, 20268-K	8-K	Earnings release — EPS $2.04 vs $2.03 est. (+0.5%); revenue $16.40B (+5% y/y) 2.2%	Feb 3, 2026

2025 · 17 filings

Filed	Form	What it is	Period
Dec 4, 20258-K	8-K	Other events	Dec 4, 2025
Nov 5, 202510-Q	10-Q	Quarterly report, Q3 2025 — revenue $17.28B (+4% y/y), net income $5.79B, EPS $2.32	Sep 30, 2025
Oct 30, 20258-K	8-K	Earnings release — EPS $2.58 vs $2.36 est. (+9.3%); revenue $17.28B (+4% y/y) 0.3%	Oct 30, 2025
Sep 9, 20258-K	8-K	Other events	Sep 9, 2025
Aug 5, 202510-Q	10-Q	Quarterly report, Q2 2025 — revenue $15.81B (−2% y/y), net income $4.43B, EPS $1.76	Jun 30, 2025
Jul 29, 20258-K	8-K	Results of operations; Exit or disposal costs	Jul 25, 2025
May 29, 20258-K	8-K	Shareholder vote results	May 27, 2025
May 7, 2025PX14A6G	PX14A6G	Shareholder exempt solicitation	—
May 2, 202510-Q	10-Q	Quarterly report, Q1 2025 — revenue $15.53B (−2% y/y), net income $5.08B, EPS $2.01	Mar 31, 2025
Apr 24, 20258-K	8-K	Results of operations	Apr 24, 2025
Apr 24, 2025PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 15, 2025ARS	ARS	Annual report to shareholders	Dec 31, 2024
Apr 14, 2025PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 9, 2025DEFA14A	DEFA14A	Additional proxy materials	—
Apr 9, 2025DEF 14A	DEF 14A	Proxy statement	May 27, 2025
Feb 25, 202510-K	10-K	Annual report, FY2024 — revenue $64.17B (+7% y/y), net income $17.12B, EPS $6.74	Dec 31, 2024
Feb 4, 20258-K	8-K	Results of operations	Feb 4, 2025

2024 · 17 filings

Filed	Form	What it is	Period
Nov 22, 20248-K	8-K	Directors or officers; compensation; Charter, bylaws or fiscal-year change	Nov 19, 2024
Nov 6, 202410-Q	10-Q	Quarterly report, Q3 2024 — revenue $16.66B (+4% y/y), net income $3.16B, EPS $1.24	Sep 30, 2024
Oct 31, 20248-K	8-K	Results of operations	Oct 31, 2024
Aug 5, 202410-Q	10-Q	Quarterly report, Q2 2024 — revenue $16.11B (+7% y/y), net income $5.46B, EPS $2.14	Jun 30, 2024
Jul 30, 20248-K	8-K	Results of operations	Jul 30, 2024
May 30, 20248-K	8-K	Shareholder vote results; Other events	May 28, 2024
May 3, 202410-Q	10-Q	Quarterly report, Q1 2024 — revenue $15.78B (+9% y/y), net income $4.76B, EPS $1.87	Mar 31, 2024
Apr 25, 20248-K	8-K	Results of operations	Apr 25, 2024
Apr 11, 2024ARS	ARS	Annual report to shareholders	Dec 31, 2023
Apr 11, 2024DEFA14A	DEFA14A	Additional proxy materials	—
Apr 11, 2024DEF 14A	DEF 14A	Proxy statement	May 28, 2024
Apr 11, 202410-K/A	10-K/A	Annual report, amended	Dec 31, 2023
Apr 1, 2024PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 28, 2024PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Feb 26, 202410-K	10-K	Annual report, FY2023 — revenue $60.12B (+1% y/y), net income $365.0M, EPS $0.14	Dec 31, 2023
Feb 20, 20248-K	8-K	Directors or officers; compensation	Feb 15, 2024
Feb 1, 20248-K	8-K	Results of operations; Exit or disposal costs	Jan 29, 2024

2023 · 18 filings — 7 × 8-K, 4 × PX14A6G, 3 × 10-Q and 4 other forms

Filed	Form	What it is	Period
Nov 3, 202310-Q	10-Q	Quarterly report, Q3 2023 — revenue $15.96B (+7% y/y), net income $4.75B, EPS $1.86	Sep 30, 2023
Aug 7, 202310-Q	10-Q	Quarterly report, Q2 2023 — revenue $15.04B (+3% y/y), net income −$5.97B, EPS −$2.35	Jun 30, 2023
May 18, 2023PX14A6G	PX14A6G	Shareholder exempt solicitation	—
May 5, 202310-Q	10-Q	Quarterly report, Q1 2023 — revenue $14.49B (−9% y/y), net income $2.82B, EPS $1.11	Mar 31, 2023
Apr 24, 2023PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 19, 2023PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 12, 2023PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 3, 2023ARS	ARS	Annual report to shareholders	Dec 31, 2022
Apr 3, 2023DEFA14A	DEFA14A	Additional proxy materials	—
Apr 3, 2023DEF 14A	DEF 14A	Proxy statement	—
Feb 24, 202310-K	10-K	Annual report, FY2022 — revenue $59.28B (+22% y/y), net income $14.52B, EPS $5.71	Dec 31, 2022

7 current reports (8-K) not listed; the year is on EDGAR.

2022 · 14 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Filed	Form	What it is	Period
Nov 3, 202210-Q	10-Q	Quarterly report, Q3 2022 — revenue $14.96B (+14% y/y), net income $3.25B, EPS $1.28	Sep 30, 2022
Aug 5, 202210-Q	10-Q	Quarterly report, Q2 2022 — revenue $14.59B (+28% y/y), net income $3.94B, EPS $1.55	Jun 30, 2022
May 13, 2022PX14A6G	PX14A6G	Shareholder exempt solicitation	—
May 5, 202210-Q	10-Q	Quarterly report, Q1 2022 — revenue $15.90B (+50% y/y), net income $4.31B, EPS $1.70	Mar 31, 2022
Apr 4, 2022DEFA14A	DEFA14A	Additional proxy materials	—
Apr 4, 2022DEF 14A	DEF 14A	Proxy statement	May 24, 2022
Feb 25, 202210-K	10-K	Annual report, FY2021 — revenue $48.70B (+17% y/y), net income $13.05B, EPS $5.14	Dec 31, 2021

7 current reports (8-K) not listed; the year is on EDGAR.

2021 · 21 filings — 14 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Filed	Form	What it is	Period
Nov 5, 202110-Q	10-Q	Quarterly report, Q3 2021 — revenue $13.15B (+20% y/y), net income $4.57B, EPS $1.80	Sep 30, 2021
Aug 9, 202110-Q	10-Q	Quarterly report, Q2 2021 — revenue $11.40B (+22% y/y), net income $1.54B, EPS $0.61	Jun 30, 2021
May 6, 2021PX14A6G	PX14A6G	Shareholder exempt solicitation	—
May 5, 202110-Q	10-Q	Quarterly report, Q1 2021 — revenue $10.63B (−12% y/y), net income $3.18B, EPS $1.25	Mar 31, 2021
Apr 5, 2021DEFA14A	DEFA14A	Additional proxy materials	—
Apr 5, 2021DEF 14A	DEF 14A	Proxy statement	May 25, 2021
Feb 25, 202110-K	10-K	Annual report, FY2020 — revenue $41.52B (+6% y/y), net income $7.07B, EPS $2.78	Dec 31, 2020

14 current reports (8-K) not listed; the year is on EDGAR.

2020 · 14 filings — 7 × 8-K, 3 × 10-Q, 2 × DEFA14A and 2 other forms

Filed	Form	What it is	Period
Nov 5, 202010-Q	10-Q	Quarterly report, Q3 2020 — revenue $10.93B (−12% y/y), net income $2.94B, EPS $1.16	Sep 30, 2020
Aug 5, 202010-Q	10-Q	Quarterly report, Q2 2020 — revenue $9.35B (−20% y/y), net income $3.00B, EPS $1.18	Jun 30, 2020
May 8, 2020DEFA14A	DEFA14A	Additional proxy materials	—
May 6, 202010-Q	10-Q	Quarterly report, Q1 2020 — revenue $12.06B (+11% y/y), net income $3.22B, EPS $1.26	Mar 31, 2020
Apr 6, 2020DEFA14A	DEFA14A	Additional proxy materials	—
Apr 6, 2020DEF 14A	DEF 14A	Proxy statement	May 26, 2020
Feb 26, 202010-K	10-K	Annual report, FY2019 — revenue $39.12B (−8% y/y), net income $9.84B, EPS $3.81	Dec 31, 2019

7 current reports (8-K) not listed; the year is on EDGAR.

2019 · 17 filings — 7 × 8-K, 3 × 10-Q, 2 × DEFA14A and 4 other forms

Filed	Form	What it is	Period
Nov 5, 201910-Q	10-Q	Quarterly report, Q3 2019 — revenue $12.40B (+15% y/y), net income $1.90B, EPS $0.74	Sep 30, 2019
Aug 6, 201910-Q	10-Q	Quarterly report, Q2 2019 — revenue $11.76B (+12% y/y), net income $2.67B, EPS $1.03	Jun 30, 2019
May 8, 201910-Q	10-Q	Quarterly report, Q1 2019 — revenue $10.82B (+8% y/y), net income $2.92B, EPS $1.12	Mar 31, 2019
May 1, 2019PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 22, 2019PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 8, 2019DEFA14A	DEFA14A	Additional proxy materials	—
Apr 8, 2019DEFA14A	DEFA14A	Additional proxy materials	—
Apr 8, 2019DEF 14A	DEF 14A	Proxy statement	May 28, 2019
Feb 27, 201910-K	10-K	Annual report, FY2018 — revenue $42.29B (+5% y/y), net income $6.22B, EPS $2.32	Dec 31, 2018

8 current reports (8-K) not listed; the year is on EDGAR.

2018 · 18 filings — 10 × 8-K, 3 × 10-Q, 3 × DEFA14A and 2 other forms

Filed	Form	What it is	Period
Nov 6, 201810-Q	10-Q	Quarterly report, Q3 2018 — revenue $10.79B (+5% y/y), net income $1.95B, EPS $0.73	Sep 30, 2018
Aug 7, 201810-Q	10-Q	Quarterly report, Q2 2018 — revenue $10.46B (+5% y/y), net income $1.71B, EPS $0.63	Jun 30, 2018
May 8, 2018DEFA14A	DEFA14A	Additional proxy materials	—
May 8, 201810-Q	10-Q	Quarterly report, Q1 2018 — revenue $10.04B, net income $736.0M, EPS $0.27	Mar 31, 2018
Apr 9, 2018DEFA14A	DEFA14A	Additional proxy materials	—
Apr 9, 2018DEFA14A	DEFA14A	Additional proxy materials	—
Apr 9, 2018DEF 14A	DEF 14A	Proxy statement	Apr 9, 2018
Feb 27, 201810-K	10-K	Annual report, FY2017 — revenue $40.12B (+1% y/y), net income $2.39B, EPS $0.87	Dec 31, 2017

10 current reports (8-K) not listed; the year is on EDGAR.

2017 · 15 filings — 7 × 8-K, 3 × 10-Q, 2 × PX14A6G and 3 other forms

Filed	Form	What it is	Period
Nov 7, 201710-Q	10-Q	Quarterly report, Q3 2017 — revenue $10.32B, net income −$56.0M, EPS −$0.02	Sep 30, 2017
Aug 8, 201710-Q	10-Q	Quarterly report, Q2 2017 — revenue $9.93B, net income $1.95B, EPS $0.71	Jun 30, 2017
May 16, 2017PX14A6G	PX14A6G	Shareholder exempt solicitation	—
May 9, 201710-Q	10-Q	Quarterly report, Q1 2017 — net income $1.55B, EPS $0.56	Mar 31, 2017
Apr 17, 2017PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 10, 2017DEFA14A	DEFA14A	Additional proxy materials	—
Apr 10, 2017DEF 14A	DEF 14A	Proxy statement	Apr 10, 2017
Feb 28, 201710-K	10-K	Annual report, FY2016 — revenue $39.81B, net income $3.92B, EPS $1.41	Dec 31, 2016

7 current reports (8-K) not listed; the year is on EDGAR.

2016 · 12 filings — 6 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2015 · 15 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2014 · 18 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2013 · 17 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2012 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2011 · 18 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2010 · 22 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2009 · 18 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2008 · 31 filings — 21 × 8-K, 3 × 10-Q, 3 × 8-K/A and 4 other forms

Counted, not listed; the year is on EDGAR.

2007 · 22 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2006 · 18 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2005 · 19 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2004 · 24 filings — 17 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2003 · 39 filings — 31 × 8-K, 3 × 10-Q, 2 × 8-K/A and 3 other forms

Counted, not listed; the year is on EDGAR.

2002 · 11 filings — 5 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2001 · 5 filings — 3 × 10-Q, 1 × 10-K, 1 × DEF 14A

Counted, not listed; the year is on EDGAR.

2000 · 6 filings — 3 × 10-Q, 1 × 10-K, 1 × 10-Q/A and 1 other form

Counted, not listed; the year is on EDGAR.

1999 · 5 filings — 3 × 10-Q, 1 × 10-K405, 1 × DEF 14A

Counted, not listed; the year is on EDGAR.

1998 · 5 filings — 3 × 10-Q, 1 × 10-K, 1 × DEF 14A

Counted, not listed; the year is on EDGAR.

1997 · 7 filings — 3 × 10-Q, 2 × 8-K, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

1996 · 8 filings — 3 × 10-K/A, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

1995 · 7 filings — 3 × 10-Q, 1 × 10-K, 1 × 10-K/A and 2 other forms

Counted, not listed; the year is on EDGAR.

1994 · 7 filings — 3 × 10-Q, 1 × 10-K, 1 × 10-K/A and 2 other forms

Counted, not listed; the year is on EDGAR.

Insider, ownership and other filings#

Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.

2026 · 120 filings — 79 × 4, 20 × 144, 3 × 11-K and 11 other forms

Filed	Form	What it is	Period
Oct 1, 20264	4	Insider transaction (Form 4)	Sep 30, 2026
Oct 1, 20264	4	Insider transaction (Form 4)	Sep 30, 2026
Oct 1, 20264	4	Insider transaction (Form 4)	Sep 30, 2026
Sep 1, 20263	3	Initial insider holdings (Form 3)	Sep 1, 2026
Aug 13, 20264	4	Insider transaction (Form 4)	Aug 13, 2026
Aug 13, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 13, 20264	4	Insider transaction (Form 4)	Aug 12, 2026
Aug 12, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 12, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 12, 20264	4	Insider transaction (Form 4)	Aug 10, 2026
Aug 11, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 10, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 10, 20264	4	Insider transaction (Form 4)	Aug 6, 2026
Aug 7, 20264	4	Insider transaction (Form 4)	Aug 5, 2026
Aug 7, 20264	4	Insider transaction (Form 4)	Aug 5, 2026
Aug 7, 20264	4	Insider transaction (Form 4)	Aug 6, 2026
Aug 7, 202613F-HR	13F-HR	Other filings	Jun 30, 2026
Aug 6, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 6, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 5, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 5, 2026144	144	Notice of proposed sale (Form 144)	—
Jul 1, 20264	4	Insider transaction (Form 4)	Jun 30, 2026
Jul 1, 20264	4	Insider transaction (Form 4)	Jun 30, 2026
Jul 1, 20264	4	Insider transaction (Form 4)	Jun 30, 2026
Jun 24, 202611-K	11-K	Employee plan annual report	Dec 31, 2025

The newest 25 of 120 shown; the full year is on EDGAR.

2025 · 95 filings — 64 × 4, 6 × 144, 4 × 13F-HR and 11 other forms

Filed	Form	What it is	Period
Dec 19, 2025SC TO-T/A	SC TO-T/A	Beneficial ownership	—
Dec 17, 2025SC TO-T/A	SC TO-T/A	Beneficial ownership	—
Dec 5, 2025SC TO-T	SC TO-T	Beneficial ownership	—
Dec 3, 2025424B5	424B5	Prospectus supplement	—
Dec 2, 2025FWP	FWP	Free writing prospectus	—
Dec 1, 2025424B5	424B5	Prospectus supplement	—
Nov 12, 202513F-HR	13F-HR	Other filings	Sep 30, 2025
Nov 12, 20254	4	Insider transaction (Form 4)	Nov 10, 2025
Nov 10, 2025144	144	Notice of proposed sale (Form 144)	—
Nov 4, 20254	4	Insider transaction (Form 4)	Nov 3, 2025
Nov 3, 2025144	144	Notice of proposed sale (Form 144)	—
Oct 2, 20254	4	Insider transaction (Form 4)	Sep 30, 2025
Oct 2, 20254	4	Insider transaction (Form 4)	Sep 30, 2025
Oct 2, 20254	4	Insider transaction (Form 4)	Sep 30, 2025
Sep 4, 2025424B5	424B5	Prospectus supplement	—
Sep 3, 2025FWP	FWP	Free writing prospectus	—
Sep 2, 2025424B5	424B5	Prospectus supplement	—
Aug 13, 202513F-HR	13F-HR	Other filings	Jun 30, 2025
Aug 5, 20254	4	Insider transaction (Form 4)	Aug 4, 2025
Aug 5, 20254	4	Insider transaction (Form 4)	Aug 4, 2025
Jul 2, 20254	4	Insider transaction (Form 4)	Jun 30, 2025
Jul 2, 20254	4	Insider transaction (Form 4)	Jun 30, 2025
Jul 2, 20254	4	Insider transaction (Form 4)	Jun 30, 2025
Jun 27, 202511-K	11-K	Employee plan annual report	Dec 31, 2024
Jun 27, 202511-K	11-K	Employee plan annual report	Dec 31, 2024

The newest 25 of 95 shown; the full year is on EDGAR.

2024 · 96 filings — 64 × 4, 11 × 144, 3 × 11-K and 12 other forms

Filed	Form	What it is	Period
Dec 23, 2024SCHEDULE 13G	SCHEDULE 13G	Other filings	—
Dec 23, 20243	3	Initial insider holdings (Form 3)	Dec 19, 2024
Nov 6, 2024SC 13G/A	SC 13G/A	Passive holder above 5% (Schedule 13G), amended	—
Nov 4, 202425-NSE	25-NSE	Delisting notice from the exchange	—
Oct 1, 20244	4	Insider transaction (Form 4)	Sep 30, 2024
Oct 1, 20244	4	Insider transaction (Form 4)	Sep 30, 2024
Oct 1, 20244	4	Insider transaction (Form 4)	Sep 30, 2024
Aug 6, 20244	4	Insider transaction (Form 4)	Aug 5, 2024
Jul 2, 20244	4	Insider transaction (Form 4)	Jun 28, 2024
Jul 2, 20244	4	Insider transaction (Form 4)	Jun 28, 2024
Jul 2, 20244	4	Insider transaction (Form 4)	Jun 28, 2024
Jun 25, 202411-K	11-K	Employee plan annual report	Dec 31, 2023
Jun 25, 202411-K	11-K	Employee plan annual report	Dec 31, 2023
Jun 25, 202411-K	11-K	Employee plan annual report	Dec 31, 2023
Jun 4, 20244	4	Insider transaction (Form 4)	May 31, 2024
Jun 4, 20244	4	Insider transaction (Form 4)	May 31, 2024
Jun 4, 20244	4	Insider transaction (Form 4)	May 31, 2024
Jun 4, 20244	4	Insider transaction (Form 4)	May 31, 2024
Jun 4, 20244	4	Insider transaction (Form 4)	May 31, 2024
Jun 4, 20244	4	Insider transaction (Form 4)	May 31, 2024
Jun 4, 20244	4	Insider transaction (Form 4)	May 31, 2024
Jun 4, 20244	4	Insider transaction (Form 4)	May 31, 2024
Jun 4, 20244	4	Insider transaction (Form 4)	May 31, 2024
Jun 4, 20244	4	Insider transaction (Form 4)	May 31, 2024
Jun 4, 20244	4	Insider transaction (Form 4)	May 31, 2024

The newest 25 of 96 shown; the full year is on EDGAR.

2023 · 110 filings — 86 × 4, 13 × 144, 3 × 11-K and 6 other forms

Counted, not listed; the year is on EDGAR.

2022 · 102 filings — 90 × 4, 5 × 3, 3 × 11-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2021 · 94 filings — 71 × 4, 8 × 3, 3 × 11-K and 9 other forms

Counted, not listed; the year is on EDGAR.

2020 · 87 filings — 69 × 4, 4 × 3, 4 × SC TO-T/A and 6 other forms

Counted, not listed; the year is on EDGAR.

2019 · 112 filings — 82 × 4, 6 × 3, 4 × SC TO-T/A and 12 other forms

Counted, not listed; the year is on EDGAR.

2018 · 103 filings — 83 × 4, 6 × 3, 4 × SC 13G/A and 6 other forms

Counted, not listed; the year is on EDGAR.

2017 · 84 filings — 67 × 4, 3 × 11-K, 3 × 4/A and 5 other forms

Counted, not listed; the year is on EDGAR.

2016 · 100 filings — 80 × 4, 4 × SC 13G/A, 3 × 11-K and 9 other forms

Counted, not listed; the year is on EDGAR.

2015 · 97 filings — 73 × 4, 6 × SC TO-T/A, 4 × 3 and 8 other forms

Counted, not listed; the year is on EDGAR.

2014 · 137 filings — 95 × 4, 12 × SC TO-T/A, 6 × SC TO-C and 15 other forms

Counted, not listed; the year is on EDGAR.

2013 · 75 filings — 63 × 4, 5 × 11-K, 2 × 424B5 and 4 other forms

Counted, not listed; the year is on EDGAR.

2012 · 104 filings — 79 × 4, 5 × 11-K, 5 × NO ACT and 7 other forms

Counted, not listed; the year is on EDGAR.

2011 · 122 filings — 97 × 4, 5 × 11-K, 3 × CORRESP and 9 other forms

Counted, not listed; the year is on EDGAR.

2010 · 145 filings — 116 × 4, 7 × NO ACT, 5 × 11-K and 9 other forms

Counted, not listed; the year is on EDGAR.

2009 · 180 filings — 93 × 4, 28 × 3, 17 × 425 and 16 other forms

Counted, not listed; the year is on EDGAR.

2008 · 66 filings — 50 × 4, 4 × NO ACT, 3 × UPLOAD and 6 other forms

Counted, not listed; the year is on EDGAR.

2007 · 77 filings — 43 × 4, 4 × 424B2, 4 × 424B3 and 11 other forms

Counted, not listed; the year is on EDGAR.

2006 · 93 filings — 76 × 4, 3 × CORRESP, 3 × NO ACT and 6 other forms

Counted, not listed; the year is on EDGAR.

2005 · 64 filings — 47 × 4, 6 × NO ACT, 3 × SC 13G/A and 6 other forms

Counted, not listed; the year is on EDGAR.

2004 · 100 filings — 83 × 4, 2 × 11-K, 2 × 3 and 10 other forms

Counted, not listed; the year is on EDGAR.

2003 · 117 filings — 94 × 4, 4 × 3, 3 × 4/A and 10 other forms

Counted, not listed; the year is on EDGAR.

2002 · 8 filings — 3 × NO ACT, 2 × 11-K, 2 × SC 13G/A and 1 other form

Counted, not listed; the year is on EDGAR.

2001 · 4 filings — 2 × 11-K, 2 × SC 13G/A

Counted, not listed; the year is on EDGAR.

2000 · 4 filings — 2 × 11-K, 1 × SC 13G, 1 × SC 13G/A

Counted, not listed; the year is on EDGAR.

1999 · 4 filings — 2 × 11-K, 1 × S-8, 1 × SC 13G/A

Counted, not listed; the year is on EDGAR.

1998 · 4 filings — 2 × 11-K, 1 × 8-A12B/A, 1 × SC 13G

Counted, not listed; the year is on EDGAR.

1997 · 6 filings — 2 × 11-K, 1 × 8-A12B, 1 × 8-A12B/A and 2 other forms

Counted, not listed; the year is on EDGAR.

1996 · 2 filings — 2 × S-3

Counted, not listed; the year is on EDGAR.

1995 · 3 filings — 1 × 8-A12B/A, 1 × S-4, 1 × S-4/A

Counted, not listed; the year is on EDGAR.

1994 · 1 filing — 1 × S-8

Counted, not listed; the year is on EDGAR.

About this data

Merck & Co. Inc. (MRK) has 3,028 filings on EDGAR going back to 1994: 42 annual reports, 99 quarterly reports and 280 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Aug 4, 2026, covered results of operations. Over the last 13 months insiders sold $70.7M in 21 sales and bought nothing on the open market; 120 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.

Every row is a filing EDGAR lists for the registrants that have been Merck & Co. Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.

FAQ#

Where can I read MRK's latest 10-K?: MRK's latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
When did MRK last file an 8-K?: On Aug 4, 2026: results of operations. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 4, 2026.
Are MRK insiders buying or selling?: Over the last 13 months insiders sold $70.7M in 21 sales and bought nothing on the open market; 120 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Guindo Chirfi (EVP, Access, Policy & Comms) sold 10,000 shares on Aug 13, 2026 for $1.4M. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
How many SEC filings has MRK made?: 3,028 filings are on EDGAR under the registrant records that have been Merck & Co. Inc., going back to 1994; 2,020 of them are insider ownership forms (Forms 3, 4, 5 and 144).

MRK SEC filings (2026)

What happened, last 12 months#

August 2026

May 2026

April 2026

February 2026

December 2025

November 2025

October 2025

Insider transactions#

Reports and proxy statements#

Insider, ownership and other filings#

About this data

FAQ#